CRISPR Therapeutics shareholders approve 1M share increase to equity plan, elect two new directors

CRISPR Therapeutics AG

Amendment to 2018 Stock Option Plan adding 1,000,000 common shares to reserve approved (34.3M for, 8.5M against).
Sandesh Mahatme and Christian Rommel elected as new Board members; all incumbent directors re-elected.
Articles of Association amended: capital band increased to CHF 3,100,452; equity/pension practices updated.
Binding vote on Board equity grants passed 32.2M for vs 10.7M against; 2023 compensation report endorsed non-binding.
Proposal to transact other business was rejected (21.9M against, 20.3M for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.